NOMAD POWER SOLUTIONS, INC. Additional Paid in Capital, Common Stock
NOMAD POWER SOLUTIONS, INC. (NMAD) had Additional Paid in Capital, Common Stock of $15.71 million as of 2014-09-30, per its 10-Q filed 2014-11-12.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2014-11-12
- 2014-09-30: Additional Paid in Capital, Common Stock $15.71M.
- 2014-06-30: Additional Paid in Capital, Common Stock $15.59M.
- 2014-03-31: Additional Paid in Capital, Common Stock $13.78M.
- 2013-12-31: Additional Paid in Capital, Common Stock $13.18M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2014-09-30 | $15.71M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $15.59M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $13.78M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $13.18M 10-Q · filed 2014-11-12 |
| 2013-09-30 | $13.17M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $13.15M 10-Q · filed 2013-08-05 |
| 2013-03-31 | $13.12M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $13.06M 10-K · filed 2014-03-21 |
| 2012-09-30 | $13.01M 10-Q · filed 2012-11-13 |
| 2012-06-30 | $11.22M 10-Q · filed 2012-08-10 |
| 2012-03-31 | $8.32M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $8.07M 10-K · filed 2013-03-15 |
| 2011-09-30 | $7.96M 10-Q · filed 2011-11-10 |
| 2011-06-30 | $77.09M 10-Q · filed 2011-08-12 |
| 2010-12-31 | $7.66M 10-K · filed 2012-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |